Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1β, matrix metalloprotease-9, and cartilage damage in arthritis

Experimental Biology and Medicine

Volumn 230, Issue 4, 2005, Pages 255-262

  Chou, May M ^a   Vergnolle, Nathalie ^a   McDougall, Jason J ^a   Wallace, John L ^a   Marty, Stephanie ^a   Teskey, Val ^b   Buret, Andre G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b New Era Nutrition Inc   (Canada)

Author keywords

Cartilage; Chondroitin; Glucosamine; IL 1 ; MMP 9

Indexed keywords

CHONDROITIN SULFATE; FREUND ADJUVANT; GELATINASE B; GLUCOSAMINE SULFATE; INTERLEUKIN 1BETA;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE DEGENERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; EDEMA; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; RAT; WALKING;

EID: 16444368593     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020523000405     Document Type: Article

References (57)

1. Bacon PA, Farr M. Assessment of rheumatoid arthritis. Curr Opin Rheumatol 3:421-428, 1991.
2. Bardwell WA, Nicassio PM, Weisman MH, Gevirtz R, Bazzo D. Rheumatoid arthritis severity scale: a brief, physician-completed scale not confounded by patient self-report of psychological functioning. Rheumatology 41:38-45, 2002.
3. McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 25:215-233, 1996.
4. Fenton JI, Chlebek-Brown KA, Caron JP, Orth MW. Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet J 34(Suppl):219-223, 2002.
5. Firestein GS. The immunopathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 3:398-406, 1991.
6. Morris EA, McDonald BS, Webb AC, Rosenwasser LJ. Identification of interleukin-1 in equine osteoarthritic joint effusions. Am J Vet Res 51:59-64, 1990.
7. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis Rheum 44:585-594, 2001.
8. Clegg PD, Carter SD. Matrix metalloproteinase-2 and -9 are activated in joint diseases. Equine Vet J 31:324-330, 1999.
9. Hirose T, Reife RA, Smith GN Jr, Stevens RM, Mainardi CL, Hasty KA. Characterization of type V collagenase (gelatinase) in synovial fluid of patients with inflammatory arthritis. J Rheumatol 19:593-599, 1992.
10. Sopata I, Wize J, Filipowicz-Sosnowska A, Stanislawska-Biernat E, Brzezinska B, Maslinski S. Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases. Rheumatol Int 15:9-14, 1995.
11. Tetlow LC, Lees M, Ogata Y, Nagase H, Woolley DE. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int 13:53-59, 1993.
12. Wang X, Liang J, Koike T, Sun H, Ichikawa T, Katajima S, Morimoto M, Shikama H, Watanabe T, Sasaguri Y, Fan J. Overexpression of human metallo-proteinase 12 enhances the development of inflammatory arthritis in transgenic rabbits. Am J Pathol 165:1375-1383, 2004.
13. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 15:805-829, 2001.
14. Borkakoti N. Matrix metalloprotease inhibitors: design from structure. Biochem Soc Trans 32:17-20, 2004.
15. Klimiuk PA, Sierakowski S, Domyslawska J, Chwiecko J. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31:238-242, 2004.
16. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929-1933, 1999.
17. Manek NJ, Lane NE. Osteoarthritis: current concepts in diagnosis and management. Am Fam Physician 61:1795-1804, 2000.
18. Manek NJ. Medical management of osteoarthritis. Mayo Clin Proc 76:533-539, 2001.
19. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899, 1999.
20. de los Reyes GC, Koda RT, Lien EJ. Glucosamine and chondroitin sulfates in the treatment of osteoarthritis. Prog Drug Res 55:81-103, 2000.
21. Hoffman AR. Treatment with Cosequin of bilateral coxofemoral osteoarthritis in a Great Dane. Compendium Oct:888-893, 2001.
22. Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneimittelforschung 36:729-735, 1986.
23. Oegema TR Jr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 46:2495-2503, 2002.
24. Bassleer CT, Combal JA, Bougaret S, Malaise M. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 6:196-204, 1998.
25. Hauselmann HJ. Nutripharmaceuticals for osteoarthritis. Best Pract Res Clin Rheumatol 15:595-607, 2001.
26. Orth MW, Peters TL, Hawkins JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine Vet J 34(Suppl):224-229, 2002.
27. Beren J, Hill SL, Diener-West M, Rose NR. Effect of preloading oral glucosamine HCl/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats. Exp Biol Med 226:144-151, 2000.
28. McNamara PS, Barr SC, Erb HN. Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Am J Vet Res 57:1390-1394, 1996.
29. Canapp SO, McLaughlin RM, Hoskinson JJ, Roush JK, Butine MD. Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate. Am J Vet Res 60:1552-1557, 1999.
30. Johnson KA, Hulse DA, Hart RC, Kochevar D, Chu Q. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarthritis Cartilage 9:14-21, 2001.
31. Lippiello L, Woodward J, Karpman R, Hammad T. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop 381:229-240, 2000.
32. Hanson RR, Brawner WR, Blaik MA, Hammad TA, Kincaid SA, Pugh DG. Oral treatment with a nutraceutical (Cosequin) for ameliorating signs of navicular syndrome in horses. Vet Ther 2:148-159, 2001.
33. Das A Jr, Hammad TA. Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage 8:343-350, 2000.
34. Kelly GS. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev 3:27-39, 1998.
35. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology 41:279-284, 2002.
36. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. Rheum Dis Clin North Am 25:379-395, 1999.
37. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 50:767-770, 2001.
38. Cicala C, Ianaro A, Fiorucci S, Calignano M, Buci M, Gerli R, Santucci L, Wallace JL. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol 130:1399-1405, 2000.
39. Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz J-L, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs. chondroitin sulfate 3,400 mg/day vs. placebo. Osteoarthritis Cartilage 6(Suppl A):25-30, 1998.
40. Gaby AR. Natural treatments for osteoarthritis. Altern Med Rev 4:330-341, 1999.
41. Uebelhart D, Thonar E, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 6(Suppl A):39-46, 1998.
42. Pearson CM, Waksman BH, Sharp JT. Studies of arthritis and other lesions induced in rats by injection of mycobacterial adjuvant. V. Changes affecting the skin and mucous membranes. Comparison of the experimental process with human disease. J Exp Med 113:485-510, 1961.
43. Pearson CM. Experimental joint disease observations on adjuvant-induced arthritis. J Chronic Dis 16:863-874, 1963.
44. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 127:1083-1090, 1999.
45. Vergnolle N, Hollenberg MD, Wallace JL. Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1 ). Br J Pharmacol 126:1262-1268, 1999.
46. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD, Wallace JL. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 7:821-826, 2001.
47. Asfaha S, Brussee V, Chapman K, Zochodne DW, Vergnolle N. Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br J Pharmacol 135:1101-1106, 2002.
48. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metallo-proteinase-2 and matrix-metalloproteinase-9 in antibody-induced arthritis. J Immunol 169:2643-2647, 2002.
49. Tchetverikov I, Ronday HK, Van El B, Kiers GH, Verzijl N, TeKoppele JM, Huizinga TW, DeGroot J, Hanemaaijer R. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 63:881-883, 2004.
50. Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 22:335-338, 2004.
51. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 71:632-640, 2002.
52. Meininger CJ, Kelly KA, Li H, Haynes TE, Wu G. Glucosamine inhibits inducible nitric oxide synthesis. Biochem Biophys Res Commun 279:234-239, 2000.
53. Lippiello L. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage 11:335-342, 2003.
54. Creamer P, Hochberg MC. Osteoarthritis. Lancet 350:503-509, 1997.
55. Mitrovic D, McCall E, Dray F. The in vitro production of prostanoids by cultured bovine articular chondrocytes. Prostaglandins 23:17-28, 1982.
56. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M. Interleukin-1 beta down-regulates the expression of glucuronosyltransferase 1, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1 beta-mediated effects in rat chondrocytes. Arthritis Rheum 44:351-360, 2001.
57. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305-315, 1990.